Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [1] Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study
    Tang, Monica
    Schaffer, Andrea L.
    Kiely, Belinda E.
    Daniels, Benjamin
    Lee, Chee K.
    Simes, Robert J.
    Pearson, Sallie-Anne
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 893 - 902
  • [2] Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
    Benjamin Daniels
    Belinda E Kiely
    Nehmat Houssami
    Sarah J Lord
    Timothy Dobbins
    Christine Y Lu
    Robyn L Ward
    Sallie-Anne Pearson
    British Journal of Cancer, 2018, 118 : 441 - 447
  • [3] Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014)
    Daniels, Benjamin
    Kiely, Belinda E.
    Houssami, Nehmat
    Lord, Sarah J.
    Dobbins, Timothy
    Lu, Christine Y.
    Ward, Robyn L.
    Pearson, Sallie-Anne
    BRITISH JOURNAL OF CANCER, 2018, 118 (03) : 441 - 447
  • [4] Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients
    Zurawska, U.
    Baribeau, D. A.
    Giilck, S.
    Victor, C.
    Gandhi, S.
    Florescu, A.
    Verma, S.
    CURRENT ONCOLOGY, 2013, 20 (06) : E539 - E545
  • [5] Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
    Canale, Maria laura
    Casolo, Giancarlo
    Donati, Sara
    Bisceglia, Irma
    Puccetti, Cheti
    Amoroso, Domenico
    Venturini, Elio
    Maurea, Nicola
    Turazza, Fabio maria
    Camerini, Andrea
    IN VIVO, 2023, 37 (05): : 2139 - 2146
  • [6] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [7] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer
    Sonke, Gabe S.
    Mandjes, Ingrid A.
    Holtkamp, Marjo J.
    Schot, Margaret
    van Werkhoven, Erik
    Wesseling, Jelle
    Peeters, Marie-Jeanne Vrancken
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    BREAST JOURNAL, 2013, 19 (04) : 419 - 426
  • [8] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [9] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [10] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
12345